TrialBreast (Edinburgh, Scotland)2023

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).

Thomas Decker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.